Cost-effectiveness analysis of treatment with epoietin-α for patients with anaemia due to renal failure: The case of Sweden

Scandinavian Journal of Urology and Nephrology

Volumn 42, Issue 1, 2008, Pages 66-73

  Glenngård, Anna H ^a   Persson, Ulf ^a   Schön, Staffan ^b  

^a SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^b RYHOV COUNTY HOSPITAL   (Sweden)

Author keywords

Anaemia; Cost effectiveness; Epoietin ; Renal failure; Sweden

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEMODIALYSIS; HOSPITAL COST; HOSPITALIZATION; HUMAN; IRON THERAPY; KIDNEY FAILURE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SWEDEN; UNITED KINGDOM;

ANEMIA; COST-BENEFIT ANALYSIS; EPOETIN ALFA; ERYTHROCYTE TRANSFUSION; FEMALE; HEALTH CARE COSTS; HEMATINICS; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; SWEDEN; TREATMENT OUTCOME;

EID: 38349174791     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/00365590701561994     Document Type: Article

References (36)

1. Locatelli F, Pisoni RL, Akizawa T, Cruz JM, DeOreo PB, Lamiere NH, et al. Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. Am J Kidney Dis 2004;44:S27-33.
2. Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:94-111.
3. Riktlinjer för omhändertagande av patienter med njursvikt (Clinical practice guidelines for renal failure patients in Sweden). Svensk Njurmedicinsk Förening (Swedish Renal Association). Göteborg; 2000.
4. Remák E, Hutton J, Jones M, Zagari M. Changes in cost-effectiveness over time. The case of Epoetin Alfa for renal replacement therapy patients in the UK. Eur J Health Econ 2003;4:115-21.
5. Dialys i Sverige 2004 (Dialysis in Sweden 2004). SDDB, Svensk Njurmedicinsk Förening (Swedish Dialysis Database, Swedish Renal Association). Göteborg; 2005.
6. Nationella tvärsnittsundersökningen Hösten 2002 (National cross sectional survey - Fall 2002). SDDB, Svensk Njurmedicinsk Förening (Swedish Dialysis Database, Swedish Renal Association). Göteborg; 2003.
7. www.medscinet.com/sddb
8. Aktiv uremivård i Sverige 1991-2004 (Active treatment of uremia in Sweden 1991-2004). SRAU (Swedish Registry for Active Treatment of Uremia). Göteborg; 2005.
9. The Swedish Association of the Pharmaceutical Industry/FASS. Pharmaceutical Specialities in Sweden. Stockholm: Linfo; 2007. Available from: www.fass.se
10. Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007;11:1-220.
11. Southern Regional Health Care Board. Prices and reimbursements for the Southern Health Care Region, 2007. Southern Regional Health Care Board. Lund; 2006. Available from: www.srvn.org
12. Furuland H, Linde T, Ahlmén J, Christensson A, Strömbom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoietin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003;18:353-61.
13. Crémieux PY, Barrett B, Anderson K, Slavin MB. Cost of outpatient blood transfusion in cancer patients. J Clin Oncol 2000;18:2755-61.
14. Sonnenberg FA, Gregory P, Yomtovian GR, Russel LB, Tierney W, Kosmin M, et al. The cost-effectiveness of autologous transfusion revisited: implications of an increased risk of bacterial infection with allogeneic transfusion. Transfusion 1999;39:808-17.
15. Shanwell A. Blodtransfusion aldrig helt biverkningsfri - Filtrerade erytrocytkoncentrat bör användas (Blood transfusion is never completely without side-effects. Filtrated erythrocyte concentrates should be used). Läkartidningen 2000;97:1782-7.
16. Berseus O, Norda R. Kartläggning av Sveriges blodförsö rjning 2002. Stockholm: Socialstyrelsen; 2004.
17. Coyle D, Lee KM, Fergusson D, Laupacis A. Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery. Pharmacoeconomics 2000;18:161-71.
18. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 1990;300:573-8.
19. Stevens MR, Summerfield GP, Hall AA, Bech CA, Harding A, Cove-Smith JR, et al. Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease. Br Med J 1992;304:474-7.
20. Moreno F, Aracil FJ, Perez R, Valderrabano F. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis 1996;27:548-56.
21. Muirhead N, Laupacis A, Wong C. Erythropoietin for anaemia in haemodialysis patients: results of a maintenance study (the Canadian Erythropoietin Study Group). Nephrol Dial Transplant 1992;7:811-6.
22. Harris DCH, Lawrence S, Chapman JR, Roger SD, Stewart JH. Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysis. Aust N Z J Med 1991;21:693-700.
23. Leese B, Hutton J, Maynard AK. The costs and benefits of the use of erythropoietin in the treatment of anaemia arising from chronic renal failure: a European study. York, UK: Centre for Health Economics, University of York; 1990.
24. Tonelli M, Winkelmayer WC, Jindal KK, Owen WF, Manns BJ. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int 2003;64:295-304.
25. Perlman RL, Finkelstein FO, Liu L, Roys E, Kiser M, Eisele G, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis 2005;45:658-66.
26. Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Curr Med Res Opin 2006;22:1929-37.
27. Merkus MP, Jager KJ, Dekker FW, Boeschoten EW, Stevens P, Krediet RT. Quality of life in patients on chronic dialysis: self-assessment 3 months after the start of treatment. Am J Kidney Dis 1997;29:584-92.
28. Manns B, Johnson JA, Taub K, Mortis G, Ghali WA, et al. Quality of life in patients treated with hemodialysis or peritoneal dialysis: what are the important determinants? Clin Nephrol 2003;60:341-51.
29. Churchill WH, Torrance GW, Taylor DW, Barnes CC, Ludwin D. Measurement of quality of life in end-stage renal disease: the time-trade-off approach. Clin Invest Med 1987;1:14-20.
30. De Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy 1998;44:215-32.
31. Merkus MP, Jager KJ, Dekker FW, De Haan RJ, Boeschoten EW, Krediet RT. Quality of life over time in dialysis: the Netherlands Cooperative Study on the Adequacy of Dialysis. Kidney Int 1999;56:720-8.
32. The Swedish Pharmaceutical Benefits Board. General guidelines regarding economic evaluations. Solna, Sweden: The Swedish Pharmaceutical Benefits Board; 2003 (in Swedish).
33. Rayner HC, Pisoni RL, Bommer J, Canaud B, Hecking E, Locatelli F, et al. Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004;19:108-20.
34. Persson U, Hjelmgren J. Health services need knowledge of how the public values health. Läkartidningen 2003;100:3436-7 (in Swedish).
35. Ansell D, Feest T, Byrne C, Ahmad A. UK Renal Registry Report 2003: The sixth annual report. Bristol, UK: The Renal Association, UK Renal Registry; 2003. Available from: http:/www.renalreg.com/Report%202003/Cover3_Frames.htm
36. Swedish National Board of Health and Welfare. Patient data register of the Swedish National Board of Health and Welfare. Swedish National Board of Health and Welfare, Stockholm; 2007.